User profiles for J A Monn

James Monn

VP Discovery Chemistry, Karuna Therapeutics
Verified email at karunatx.com
Cited by 11116

Pharmacological agents acting at subtypes of metabotropic glutamate receptors

DD Schoepp, DE Jane, JA Monn - Neuropharmacology, 1999 - Elsevier
Metabotropic (G-protein-coupled) glutamate (mGlu) receptors have now emerged as a
recognized, but still relatively new area of excitatory amino acid research. Current understanding …

Metabotropic glutamate receptors as novel targets for anxiety and stress disorders

…, M Bures, MP Johnson, AM Linden, JA Monn… - Nature reviews Drug …, 2005 - nature.com
Anxiety and stress disorders are the most commonly occurring of all mental illnesses, and
current treatments are less than satisfactory. So, the discovery of novel approaches to treat …

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

…, AB Smulevich, VA Tochilov, BG Johnson, JA Monn… - Nature medicine, 2007 - nature.com
Schizophrenia is a chronic, complex and heterogeneous mental disorder, with pathological
features of disrupted neuronal excitability and plasticity within limbic structures of the brain. …

Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia

MJ Fell, DL McKinzie, JA Monn, KA Svensson - Neuropharmacology, 2012 - Elsevier
Schizophrenia is a devastating chronic psychotic disorder characterized by positive, negative,
and cognitive symptoms. Although the positive symptoms are relatively well controlled by …

Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo [3.1. 0] hexane-2, 6-dicarboxylic acid (LY354740): a potent, selective, and orally active …

JA Monn, MJ Valli, SM Massey, RA Wright… - Journal of medicinal …, 1997 - ACS Publications
2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (9) was designed as a conformationally
constrained analog of glutamic acid. For 9, the key torsion angles (τ 1 and τ 2 ) which …

Physiological antagonism between 5-hydroxytryptamine2A and group II metabotropic glutamate receptors in prefrontal cortex

GJ Marek, RA Wright, DD Schoepp, JA Monn… - … of Pharmacology and …, 2000 - ASPET
In prefrontal cortex, 5-hydroxytryptamine 2A (5-HT 2A ) receptors have been linked to the
action of hallucinogens and atypical antidepressant/antipsychotic drugs. Previously, we have …

Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo [3.1. 0] hexane-2, 6-dicarboxylic acid …

JA Monn, MJ Valli, SM Massey… - Journal of medicinal …, 1999 - ACS Publications
As part of our ongoing research program aimed at the identification of highly potent, selective,
and systemically active agonists for group II metabotropic glutamate (mGlu) receptors, we …

Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors

DR Helton, JP Tizzano, JA Monn, DD Schoepp… - … of Pharmacology and …, 1998 - ASPET
LY354740 is a conformationally constrained analog of glutamate which is a potent agonist
for group II cAMP coupled metabotropic glutamate receptors (mGluRs). The discovery of this …

The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats

J Cartmell, JA Monn, DD Schoepp - Journal of Pharmacology and …, 1999 - ASPET
Previous animal studies have indicated that drugs targeted at metabotropic glutamate (mGlu)
receptors may be useful for treatment of psychosis. In this article, the effects of the novel, …

LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors

…, JP Burnett, R Belegaje, D Bleakman, JA Monn - …, 1997 - Elsevier
The novel compound LY354740 is a conformationally constrained analog of glutamate, which
was designed for interaction at metabotropic glutamate (mGlu) receptors. In this paper the …